Eddy Arnold

发表

Adventures in Small Molecule Fragment Screening by X-ray Crystallography

Joseph D. Bauman, Disha Patel, Eddy Arnold, 2015 .

The RNA Polymerase “Switch Region” Is a Target for Inhibitors

Jayanta Mukhopadhyay, Eddy Arnold, Rolf Jansen, 2008, Cell.

Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability.

Paul J Lewi, Eddy Arnold, A. D. Clark, 2005, Journal of medicinal chemistry.

Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.

William L Jorgensen, Eddy Arnold, W. L. Jorgensen, 2013, Bioorganic & medicinal chemistry letters.

Correction to Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet.

Jan Balzarini, Matthew T Miller, Eddy Arnold, 2016, ACS Chemical Biology.

Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.

Christophe Meyer, Stephen H Hughes, Eddy Arnold, 2005, Journal of medicinal chemistry.

Structural and Molecular Interactions of CCR5 Inhibitors with CCR5*

Yasushi Tojo, Eddy Arnold, Debananda Das, 2006, Journal of Biological Chemistry.

Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae

Sony Malhotra, Tom L Blundell, Eddy Arnold, 2018, Scientific Reports.

Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.

Stephen H Hughes, Paul J Lewi, Eddy Arnold, 2005, Progress in biophysics and molecular biology.

Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening.

Eddy Arnold, Sameer Ahmed, A. Shatkin, 2013, Journal of medicinal chemistry.

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations

Stephen H Hughes, Paul J Lewi, Eddy Arnold, 2008, Proceedings of the National Academy of Sciences.

Crystal structure of RlmAI: Implications for understanding the 23S rRNA G745/G748-methylation at the macrolide antibiotic-binding site

Gaetano T Montelione, Eddy Arnold, G. Montelione, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Structural basis of BLyS receptor recognition

Eddy Arnold, E. Arnold, R. Gentz, 2002, Nature Structural Biology.

Discovery and Characterization of Fluorine-Substituted Diarylpyrimidines Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.

Peng Zhan, Dongwei Kang, Yanying Sun, 2020, Journal of medicinal chemistry.

4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.

Christophe Meyer, Eddy Arnold, Koen Andries, 2005, Journal of medicinal chemistry.

Structures of influenza A proteins and insights into antiviral drug targets

James M Aramini, Eddy Arnold, Li-Chung Ma, 2010, Nature Structural &Molecular Biology.

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism

Joseph D. Bauman, Eddy Arnold, E. Arnold, 2012, Nature Structural &Molecular Biology.

Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery.

Eddy Arnold, E. Arnold, J. Bauman, 2014, Progress in biophysics and molecular biology.

Rapid experimental SAD phasing and hot-spot identification with halogenated fragments

Joseph D. Bauman, Eddy Arnold, E. Arnold, 2016, IUCrJ.

Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailability.

Emilio Gallicchio, Ronald M Levy, Eddy Arnold, 2009, Journal of medicinal chemistry.

Structural Basis of Mycobacterium tuberculosis Transcription and Transcription Inhibition.

Nancy D. Connell, Eddy Arnold, Shengjian Li, 2017, Molecular cell.

Exploring structural variability in X-ray crystallographic models using protein local optimization by torsion-angle sampling.

Richard A Friesner, Jennifer L. Knight, Emilio Gallicchio, 2008, Acta crystallographica. Section D, Biological crystallography.

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

Stephen H Hughes, Peter Williams, Paul J Lewi, 2005, Journal of medicinal chemistry.

In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.

Emilio Gallicchio, Ronald M Levy, Eddy Arnold, 2009, Journal of molecular biology.

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

Joseph D. Bauman, Aaron J. Shatkin, Stephen H. Hughes, 2008, Nucleic acids research.

Structure of HIV-1 RT/dsRNA initiation complex prior to nucleotide incorporation

Eddy Arnold, Jeffrey J. DeStefano, E. Arnold, 2019, Proceedings of the National Academy of Sciences.

Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures.

Omar Haq, Ronald M Levy, Anthony K Felts, 2009, Journal of medicinal chemistry.

Linear Interaction Energy (LIE) Models for Ligand Binding in Implicit Solvent: Theory and Application to the Binding of NNRTIs to HIV-1 Reverse Transcriptase.

Emilio Gallicchio, Ronald M Levy, Eddy Arnold, 2007, Journal of chemical theory and computation.